GT200200039A - Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos - Google Patents

Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos

Info

Publication number
GT200200039A
GT200200039A GT200200039A GT200200039A GT200200039A GT 200200039 A GT200200039 A GT 200200039A GT 200200039 A GT200200039 A GT 200200039A GT 200200039 A GT200200039 A GT 200200039A GT 200200039 A GT200200039 A GT 200200039A
Authority
GT
Guatemala
Prior art keywords
strogens
agonists
invested
gaba
vitamin
Prior art date
Application number
GT200200039A
Other languages
English (en)
Inventor
Anabella Villalobos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200039A publication Critical patent/GT200200039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCION SE REFIERE A AGONISTAS INVERSOS DE GABA A EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E, DE FORMULA GENERAL (I) EN DONDE Y,X, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON UTILES EN ENFERMEDADES DE DISFUNCION COGNITIVA TALES COMO ENFERMEDAD DE ALZHEIMER, PARKINSON, HUNTINGTON, APOPLEJIA, DEMENCIA ASOCIADA CON EL SIDA, TRASTORNOS DE DEFICIT DE ATENCION.
GT200200039A 2001-03-01 2002-02-27 Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos GT200200039A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27256601P 2001-03-01 2001-03-01

Publications (1)

Publication Number Publication Date
GT200200039A true GT200200039A (es) 2002-11-21

Family

ID=23040351

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200039A GT200200039A (es) 2001-03-01 2002-02-27 Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos

Country Status (33)

Country Link
US (2) US20020193360A1 (es)
EP (1) EP1363606A1 (es)
JP (1) JP2004527500A (es)
KR (1) KR20030076717A (es)
CN (1) CN1494422A (es)
AP (1) AP2002002465A0 (es)
AR (1) AR033425A1 (es)
BG (1) BG108131A (es)
BR (1) BR0207802A (es)
CA (1) CA2439581A1 (es)
CR (1) CR7059A (es)
CZ (1) CZ20032338A3 (es)
DO (1) DOP2002000345A (es)
EA (1) EA200300854A1 (es)
EC (1) ECSP034759A (es)
EE (1) EE200300422A (es)
GT (1) GT200200039A (es)
HU (1) HUP0303448A3 (es)
IL (1) IL157465A0 (es)
IS (1) IS6905A (es)
MA (1) MA26999A1 (es)
MX (1) MXPA03007834A (es)
NO (1) NO20033821L (es)
NZ (1) NZ527397A (es)
OA (1) OA12554A (es)
PA (1) PA8540701A1 (es)
PE (1) PE20020927A1 (es)
PL (1) PL364081A1 (es)
SK (1) SK10752003A3 (es)
TN (1) TNSN02018A1 (es)
UY (1) UY27188A1 (es)
WO (1) WO2002069948A1 (es)
ZA (1) ZA200306193B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US8030300B2 (en) 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007019312A2 (en) * 2005-08-03 2007-02-15 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
CA2935516A1 (en) 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
ES2399071T3 (es) * 2006-10-16 2013-03-25 Bionomics Limited Nuevos compuestos ansiolíticos
AU2013202426B2 (en) * 2006-10-16 2015-08-06 Bionomics Limited Novel anxiolytic compounds
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
EP2121000B1 (en) 2007-02-09 2015-09-23 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
EP2268639A2 (en) * 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) * 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
RU2012102052A (ru) * 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
CN103649086A (zh) 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
AU2016279052A1 (en) 2015-06-19 2018-02-15 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
CN116008442B (zh) * 2023-03-27 2023-06-30 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) * 2023-04-10 2023-07-07 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU10500A (sh) * 1997-08-25 2002-10-18 Neurogen Corporation Supstituisani 4-okso-naptiridin-3-karboksamidi kao gaba moždani receptorski liganidi
US6448246B1 (en) * 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands

Also Published As

Publication number Publication date
NO20033821D0 (no) 2003-08-28
EA200300854A1 (ru) 2004-02-26
EP1363606A1 (en) 2003-11-26
UY27188A1 (es) 2002-10-31
HUP0303448A3 (en) 2005-05-30
CR7059A (es) 2004-03-10
OA12554A (en) 2006-06-07
PL364081A1 (en) 2004-12-13
WO2002069948A1 (en) 2002-09-12
CA2439581A1 (en) 2002-09-12
ZA200306193B (en) 2004-08-11
BG108131A (en) 2004-09-30
NO20033821L (no) 2003-09-10
HUP0303448A2 (hu) 2004-01-28
US20020193360A1 (en) 2002-12-19
PA8540701A1 (es) 2002-09-30
NZ527397A (en) 2005-05-27
TNSN02018A1 (fr) 2005-12-23
AR033425A1 (es) 2003-12-17
MXPA03007834A (es) 2003-12-08
US20040082555A1 (en) 2004-04-29
CN1494422A (zh) 2004-05-05
IS6905A (is) 2003-08-07
KR20030076717A (ko) 2003-09-26
AP2002002465A0 (en) 2002-06-30
PE20020927A1 (es) 2002-10-30
DOP2002000345A (es) 2002-12-15
CZ20032338A3 (cs) 2004-08-18
JP2004527500A (ja) 2004-09-09
ECSP034759A (es) 2003-10-28
EE200300422A (et) 2004-02-16
IL157465A0 (en) 2004-03-28
MA26999A1 (fr) 2004-12-20
SK10752003A3 (sk) 2004-08-03
BR0207802A (pt) 2004-03-09

Similar Documents

Publication Publication Date Title
GT200200039A (es) Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
GT200300219A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
HRP20090058A2 (en) Prodrugs of excitatory amino acids
UY28473A1 (es) Nuevos compuestos
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
DOP2002000429A (es) Imidazotriazinas
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
ECSP066336A (es) Derivados de 3-amino croman y 2-amino tetralin
CR8118A (es) Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
CO6362014A2 (es) Compuestos con anillos espiro - triciclicos como moduladores de beta-secretasaa y metodos de uso
GT200500297A (es) Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200600011A (es) Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
DE60335028D1 (de) Quinazolinone als kaliumkanalmodulatoren
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
UY28839A1 (es) Agentes terapeuticos
SG157231A1 (en) Substituted p-diaminobenzene derivatives
UY28815A1 (es) Agentes terapéuticos
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
CR11436A (es) Moduladores enlazados a amida y-secretasa
PA8607501A1 (es) N-[3-(3-sustituidas-pirazolo[1,5-a]pirimidin-7-il)fenil]-sulfonamidas y composiciones y metodos relacionados
UY27680A1 (es) Agonistas del receptor b3 - andrenérgicos.